{
    "2021-05-14": [
        [
            {
                "time": "",
                "original_text": "A股医药生物公司研发实力排行榜：恒瑞医药、复星医药、君实生物研发投入居前三，药明康德研发人员数量最多",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "复星医药",
                        "君实生物",
                        "药明康德",
                        "研发投入",
                        "研发人员"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "狂砸近70亿！高瓴最终还是买这家CDMO了，为什么我们提前预判到机会？",
                "features": {
                    "keywords": [
                        "高瓴",
                        "CDMO",
                        "投资",
                        "收购"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "快讯 | 药明生物与药明康德子公司合全药业成立合资公司，从事抗体偶联药物（ADCs）等生物偶联药物CDMO服务",
                "features": {
                    "keywords": [
                        "药明生物",
                        "药明康德",
                        "合全药业",
                        "合资公司",
                        "CDMO",
                        "ADCs"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "人口系列1：无法避免的人力成本上涨",
                "features": {
                    "keywords": [
                        "人口",
                        "人力成本",
                        "上涨"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "经济",
                        "劳动力市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明生物：与合全药业正式成立合资公司药明合联",
                "features": {
                    "keywords": [
                        "药明生物",
                        "合全药业",
                        "合资公司",
                        "药明合联"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "药明康德(02359)将每10股转增2股派3.63元",
                "features": {
                    "keywords": [
                        "药明康德",
                        "转增",
                        "派息"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}